| | |
CUSIP No. 799566104 | | Page 11 of 14 Pages |
Item 1(a). | Name of Issuer: |
Sana Biotechnology, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
188 East Blaine Street, Sute 400
Seattle, WA 98102
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Flagship V VentureLabs Rx Fund, L.P. (“Flagship Fund V Rx”)
Flagship Ventures Fund V, L.P. (“Flagship Fund V”)
Flagship Ventures Fund V General Partner LLC (“Flagship V GP”)
Flagship VentureLabs V LLC (“VentureLabs V”)
VentureLabs V Manager LLC (“VentureLabs V Manager”)
Flagship Pioneering Fund VI, L.P. (“Flagship Fund VI”)
Flagship Pioneering Fund VI General Partner LLC (“Flagship Fund VI GP”)
Flagship Pioneering, Inc. (“Flagship Pioneering”)
Noubar B. Afeyan, Ph.D. (“Dr. Afeyan”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
c/o Flagship Pioneering Inc.
55 Cambridge Parkway, Suite 800E
Cambridge, Massachusetts 02142
| | |
Flagship Fund V Rx | | Delaware |
Flagship Fund V | | Delaware |
Flagship V GP | | Delaware |
VentureLabs V | | Delaware |
VentureLabs V Manager | | Delaware |
Flagship Fund VI | | Delaware |
Flagship Fund VI GP | | Delaware |
Flagship Pioneering | | Delaware |
Dr. Afeyan | | United States of America |
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.0001 par value per share (“Common Stock”).
799566104